Induction of Cytomegalovirus-specific T Cell Responses in Healthy Volunteers and Allogeneic Stem Cell Recipients Using Vaccination with Messenger RNA-transfected Dendritic Cells

Overview

Journal Transplantation

Specialty General Surgery

Date 2014 Jul 23

PMID 25050468

Citations 15

Authors

Amaryllis H Van Craenenbroeck

Evelien L J Smits

Sebastien Anguille

Ann Van De Velde

Barbara Stein

Tessa Braeckman

Kirsten Van Camp

Griet Nijs

Margareta Ieven

Herman Goossens

Zwi N Berneman

Viggo F I Van Tendeloo

Gert A Verpooten

Pierre Van Damme

Nathalie Cools

Affiliations

Soon will be listed here.

Abstract

Background: Infection with human cytomegalovirus (CMV) is a significant cause of morbidity and mortality in solid organ and hematopoietic stem cell transplant (HSCT) recipients.

Methods: The present study explored the safety, feasibility, and immunogenicity of CMV pp65 messenger RNA-loaded autologous monocyte-derived dendritic cells (DC) as a cellular vaccine for active immunization in healthy volunteers and allogeneic HSCT recipients. Four CMV-seronegative healthy volunteers and three allogeneic HSCT recipients were included in the study. Four clinical-grade autologous monocyte-derived DC vaccines were prepared after a single leukapheresis procedure and administered intradermally at a weekly interval.

Results: De novo induction of CMV-specific T-cell responses was detected in three of four healthy volunteers without serious adverse events. Of the HSCT recipients, none developed CMV disease and one of two patients displayed a remarkable threefold increase in CMV pp65-specific T cells on completion of the DC vaccination trial.

Conclusion: In conclusion, our DC vaccination strategy induced or expanded a CMV-specific cellular response in four of six efficacy-evaluable study subjects, providing a base for its further exploration in larger cohorts.

Citing Articles

mRNA-based therapeutics: powerful and versatile tools to combat diseases.

Qin S, Tang X, Chen Y, Chen K, Fan N, Xiao W Signal Transduct Target Ther. 2022; 7(1):166.

PMID: 35597779 PMC: 9123296. DOI: 10.1038/s41392-022-01007-w.

Antiviral Cell Products against COVID-19: Learning Lessons from Previous Research in Anti-Infective Cell-Based Agents.

Chikileva I, Shubina I, Burtseva A, Kirgizov K, Stepanyan N, Varfolomeeva S Biomedicines. 2022; 10(4).

PMID: 35453618 PMC: 9027720. DOI: 10.3390/biomedicines10040868.

An overview of the recent findings of cell-based therapies for the treatment and management of COVID-19.

Ghaffari S, Kazerooni H, Salehi-Najafabadi A Int Immunopharmacol. 2021; 101(Pt B):108226.

PMID: 34634685 PMC: 8492917. DOI: 10.1016/j.intimp.2021.108226.

An outlook on antigen-specific adoptive immunotherapy for viral infections with a focus on COVID-19.

Monzavi S, Naderi M, Ahmadbeigi N, Kajbafzadeh A, Muhammadnejad S Cell Immunol. 2021; 367:104398.

PMID: 34217004 PMC: 8214814. DOI: 10.1016/j.cellimm.2021.104398.

A Guide to Nucleic Acid Vaccines in the Prevention and Treatment of Infectious Diseases and Cancers: From Basic Principles to Current Applications.

Qin F, Xia F, Chen H, Cui B, Feng Y, Zhang P Front Cell Dev Biol. 2021; 9:633776.

PMID: 34113610 PMC: 8185206. DOI: 10.3389/fcell.2021.633776.

References

Boeckh M, Leisenring W, Riddell S, Bowden R, Huang M, Myerson D . Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2002; 101(2):407-14. DOI: 10.1182/blood-2002-03-0993. View

Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Lower M . Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother. 2010; 59(10):1489-501. PMC: 2909425. DOI: 10.1007/s00262-010-0875-4. View

Van Camp K, Cools N, Stein B, Van de Velde A, Goossens H, Berneman Z . Efficient mRNA electroporation of peripheral blood mononuclear cells to detect memory T cell responses for immunomonitoring purposes. J Immunol Methods. 2010; 354(1-2):1-10. DOI: 10.1016/j.jim.2010.01.009. View

Beam E, Razonable R . Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. Curr Infect Dis Rep. 2012; 14(6):633-41. DOI: 10.1007/s11908-012-0292-2. View

Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J . Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002; 99(11):3916-22. DOI: 10.1182/blood.v99.11.3916. View

Fishman J . Infection in solid-organ transplant recipients. N Engl J Med. 2007; 357(25):2601-14. DOI: 10.1056/NEJMra064928. View

Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C . Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood. 2003; 102(13):4255-60. DOI: 10.1182/blood-2002-10-3263. View

Riddell S, Watanabe K, Goodrich J, Li C, Agha M, Greenberg P . Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992; 257(5067):238-41. DOI: 10.1126/science.1352912. View

Boeckh M, Bowden R, Goodrich J, Pettinger M, Meyers J . Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood. 1992; 80(5):1358-64. View

10.

Smits E, Berneman Z . Viral infections following allogeneic stem cell transplantation: how to cure the cure?. Leuk Lymphoma. 2010; 51(6):965-6. DOI: 10.3109/10428194.2010.487960. View

11.

Peggs K, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss P . Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet. 2003; 362(9393):1375-7. DOI: 10.1016/S0140-6736(03)14634-X. View

12.

PANDE H, Forman S, Tanamachi B, Li C, Zaia J, Greenberg P . Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol. 1994; 43(1):103-10. DOI: 10.1002/jmv.1890430119. View

13.

Nichols W, Corey L, Gooley T, Drew W, Miner R, Huang M . Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood. 2001; 97(4):867-74. DOI: 10.1182/blood.v97.4.867. View

14.

Aarntzen E, Srinivas M, Bonetto F, Cruz L, Verdijk P, Schreibelt G . Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clin Cancer Res. 2013; 19(6):1525-33. DOI: 10.1158/1078-0432.CCR-12-1879. View

15.

Trenschel R, Ross S, Husing J, Ottinger H, Elmaagacli A, Roggendorf M . Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Bone Marrow Transplant. 2000; 25(6):665-72. DOI: 10.1038/sj.bmt.1702216. View

16.

Van Gulck E, Vlieghe E, Vekemans M, Van Tendeloo V, Velde A, Smits E . mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS. 2011; 26(4):F1-12. DOI: 10.1097/QAD.0b013e32834f33e8. View

17.

Feuchtinger T, Opherk K, Bicanic O, Schumm M, Grigoleit G, Hamprecht K . Dendritic cell vaccination in an allogeneic stem cell recipient receiving a transplant from a human cytomegalovirus (HCMV)-seronegative donor: induction of a HCMV-specific T(helper) cell response. Cytotherapy. 2010; 12(7):945-50. DOI: 10.3109/14653241003587645. View

18.

Bernstein D, Reap E, Katen K, Watson A, Smith K, Norberg P . Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine. 2009; 28(2):484-93. DOI: 10.1016/j.vaccine.2009.09.135. View

19.

Van Driessche A, Van de Velde A, Nijs G, Braeckman T, Stein B, de Vries J . Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy. 2009; 11(5):653-68. DOI: 10.1080/14653240902960411. View

20.

Rowshani A, Bemelman F, van Leeuwen E, van Lier R, Ten Berge I . Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation. 2005; 79(4):381-6. DOI: 10.1097/01.tp.0000148239.00384.f0. View